1 week Ago By Defense World Staff
Legal & General Group Plc cut its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 6.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,480 shares of the company’s stock after selling 1,374 shares during the period.
Legal & General Group Plc’s holdings in MoonLake Immunotherapeutics were worth $1,055,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also recently bought and sold shares of MLTX. KLP Kapitalforvaltning AS acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $244,000.
Barclays PLC boosted its stake in MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares during the period.
Teacher Retirement System of Texas grew its position in MoonLake Immunotherapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company’s stock worth $354,000 after purchasing an additional 1,013 shares during the last quarter.
LPL Financial LLC increased its stake in MoonLake Immunotherapeutics by 19.5% in the fourth quarter. LPL Financial LLC now owns 8,146 shares of the company’s stock valued at $441,000 after purchasing an additional 1,332 shares during the period.
Finally, DnB Asset Management AS raised its holdings in shares of MoonLake Immunotherapeutics by 11.3% in the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company’s stock valued at $452,000 after buying an additional 847 shares during the last quarter.
93.85% of the stock is owned by hedge funds and other institutional investors. MoonLake Immunotherapeutics Stock PerformanceShares of MLTX opened at $39.
42 on Monday. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.
26. The stock has a 50-day moving average price of $38.67 and a 200 day moving average price of $45.
58. The company has a market capitalization of $2.52 billion, a P/E ratio of -30.
56 and a beta of 1.32. MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last issued its earnings results on Wednesday, February 26th.
The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.
09). As a group, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.
Wall Street Analysts Forecast GrowthSeveral research firms have recently commented on MLTX. Royal Bank of Canada initiated coverage on MoonLake Immunotherapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $67.
00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th.
Needham & Company LLC raised their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 27th.
Finally, The Goldman Sachs Group dropped their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.
One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Buy” and a consensus target price of $80.
50.Get Our Latest Report on MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics Profile (Free Report)MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Featured StoriesFive stocks we like better than MoonLake ImmunotherapeuticsCompound Interest and Why It Matters When InvestingTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryWhat is the S&P 500 and How It is Distinct from Other IndexesO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsAre These Liquid Natural Gas Stocks Ready For An Upside Bounce?Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report).
.
